UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity

Respiratory medicine, 2021-01, Vol.176, p.106261-106261, Article 106261

2021

Volltextzugriff (PDF)

High serum β-lactams specific/total IgE ratio is associated with immediate reactions to β-lactams antibiotics

PloS one, 2015-04, Vol.10 (4), p.e0121857-e0121857

2015

Volltextzugriff (PDF)

Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2020-09, Vol.8 (8), p.2575-2581.e2

2020

Volltextzugriff (PDF)

T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis

Frontiers in immunology, 2019-01, Vol.9, p.3113-3113

2019

Volltextzugriff (PDF)

Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome

Frontiers in immunology, 2018-05, Vol.9, p.1198-1198

2018

Volltextzugriff (PDF)

Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype

Frontiers in immunology, 2020-03, Vol.11, p.319-319

2020

Volltextzugriff (PDF)

Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia

International immunopharmacology, 2017-03, Vol.44, p.38-42

2017

Volltextzugriff (PDF)

Hapten-specific TH17 cells in the peripheral blood of β-lactam-induced AGEP

Allergology international, 2014, Vol.63 (1), p.129-131

2014

Volltextzugriff (PDF)

Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent

The Journal of clinical investigation, 2020-09, Vol.130 (9), p.4694-4703

2020

Volltextzugriff (PDF)

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

The New England journal of medicine, 2017-05, Vol.376 (20), p.1921-1932

2017

Volltextzugriff (PDF)

Heart as the early main target of severe anaphylactic reactions: two case reports

Internal and emergency medicine, 2011-10, Vol.6 (5), p.467-469

2011

Volltextzugriff (PDF)

Effectiveness of low‐dose intravenous immunoglobulin therapy in minor primary antibody deficiencies: A 2‐year real‐life experience

Clinical and experimental immunology, 2021-09, Vol.205 (3), p.346-353

2021

Volltextzugriff (PDF)

Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020

Euro surveillance : bulletin européen sur les maladies transmissibles, 2020-04, Vol.25 (17), p.1

2020

Volltextzugriff (PDF)

COVID‐19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey

Allergy (Copenhagen), 2021-03, Vol.76 (3), p.871-874

2021

Volltextzugriff (PDF)

Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies

Journal of allergy and clinical immunology, 2019-08, Vol.144 (2), p.584-593.e7

2019

Volltextzugriff (PDF)

IL-10-Producing Infliximab-Specific T Cells Regulate the Antidrug T Cell Response in Exposed Patients

The Journal of immunology (1950), 2017-08, Vol.199 (4), p.1283-1289

2017

Volltextzugriff (PDF)

"A year-long, fortnightly, observational survey in three European countries of patients with respiratory allergies induced by house dust mites: Methodology, demographics and clinical characteristics"

BMC pulmonary medicine, 2016-05, Vol.16 (1), p.85-85, Article 85

2016

Volltextzugriff (PDF)

The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2019-01, Vol.7 (1), p.339-340

2019

Volltextzugriff (PDF)

Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study

Clinical drug investigation, 2015-03, Vol.35 (3), p.179-185

2015

Volltextzugriff (PDF)

Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy

Clinical drug investigation, 2018-10, Vol.38 (10), p.955-965

2018

Volltextzugriff (PDF)

Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction

Internal and emergency medicine, 2012-09, Vol.7 (Suppl 2), p.77-79

2012

Volltextzugriff (PDF)

Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

Pulmonary pharmacology & therapeutics, 2015-04, Vol.31, p.123-129

2015

Volltextzugriff (PDF)

Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma

Immunology, 2015-09, Vol.146 (1), p.33-49

2015

Volltextzugriff (PDF)

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies

International journal of immunopathology and pharmacology, 2017-03, Vol.30 (1), p.73-82

2017

Volltextzugriff (PDF)

Delphi consensus on the current clinical and therapeutic knowledge on Anderson–Fabry disease

European journal of internal medicine, 2014-10, Vol.25 (8), p.751-756

2014

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(55)

Sprache

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity

High serum β-lactams specific/total IgE ratio is associated with immediate reactions to β-lactams antibiotics

Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study

T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis

Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome

Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype

Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia

Hapten-specific TH17 cells in the peripheral blood of β-lactam-induced AGEP

Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

Heart as the early main target of severe anaphylactic reactions: two case reports

Effectiveness of low‐dose intravenous immunoglobulin therapy in minor primary antibody deficiencies: A 2‐year real‐life experience

Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020

COVID‐19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey

Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies

IL-10-Producing Infliximab-Specific T Cells Regulate the Antidrug T Cell Response in Exposed Patients

"A year-long, fortnightly, observational survey in three European countries of patients with respiratory allergies induced by house dust mites: Methodology, demographics and clinical characteristics"

The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment

Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study

Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy

Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction

Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies

Delphi consensus on the current clinical and therapeutic knowledge on Anderson–Fabry disease

Aktive Filter

Suchergebnisse filtern